BioCryst Announces Sees Prelim. FY23 ORLADEYO Revenue $325M Vs $327.19M Est.
Portfolio Pulse from Benzinga Newsdesk
BioCryst Pharmaceuticals announced preliminary FY23 revenue for ORLADEYO at $325 million, slightly below the estimated $327.19 million.
January 05, 2024 | 9:02 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
BioCryst Pharmaceuticals' ORLADEYO revenue for FY23 is reported at $325 million, marginally below expectations.
The slight miss in revenue for ORLADEYO could lead to a negative short-term reaction in BioCryst's stock price as it may concern investors about the drug's market performance and future growth potential. However, the miss is relatively small, which might limit the negative impact.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100